CONTRATOS DE INVESTIGACIÓN
Contrato 29/2019
A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents.
Financiador:
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
date_range
Duración do 08 de marzo de 2019 ao 29 de febreiro de 2020
(12 meses)
De ámbito Internacional (non UE). Outorgouse en réxime de Concesión directa.
Investigadores/as
Gabriel de
Arriba de la Fuente
Responsable